Performer 8 Reviews: Negative Side Effects or Real Benefits?
April 22, 2021 22:46 ET | Marketing By Kevin
New York, NY, April 22, 2021 (GLOBE NEWSWIRE) -- Unfortunately for men, performance issues in the bedroom can strike at any time. Age, anxiety, and physical health issues can all interfere with a...
clarus_final_indentity.jpg
Clarus Announces JATENZO® (Testosterone Undecanoate) Capsules, CIII Now Covered by Express Scripts
December 07, 2020 09:00 ET | Clarus Therapeutics, Inc.
JATENZO is the first and only FDA-approved oral testosterone replacement therapy of its kind Coverage effective December 1, 2020 on the Express Scripts National Preferred, Basic and High Performance...
clarus_final_indentity.jpg
CLARUS THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT THE COMMERCIAL LAUNCH AND AVAILABILITY OF JATENZO® (TESTOSTERONE UNDECANOATE) CAPSULES, CIII FOR THE TREATMENT OF HYPOGONADISM
March 16, 2020 08:00 ET | Clarus Therapeutics, Inc.
Financing to speed commercialization of the only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., March 16, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics,...
Iaso logo.png
IASO BioMed Announces Addition of Four Members to Its Scientific Advisory Board
November 13, 2018 09:00 ET | IASO BioMed, Inc.
Company developing a Next Generation Treatment for Low Testosterone CENTENNIAL, Colo., Nov. 13, 2018 (GLOBE NEWSWIRE) -- IASO BioMed, Inc. (“IASO” or the “Company”), an innovative biotechnology...
Diet Doc Diet and Weight Loss Logo
Diet Doc Partners with AMG to Offer Bioidentical Hormone Replacement Therapy to Patients Nationwide
February 10, 2016 04:05 ET | Diet Doc Diet and Weight Loss
HOUSTON, Feb. 10, 2016 (GLOBE NEWSWIRE) -- The side effects of hormonal imbalance are plentiful, causing a range of symptoms from fatigue, depression, headaches and even reduced libido. Hormones can...
clarus_final_indentity.jpg
Clarus Therapeutics Top-line Results Show Oral Testosterone Replacement Candidate, CLR-610, Meets Phase 3 Study Primary Efficacy Endpoint
September 25, 2012 08:00 ET | Clarus Therapeutics, Inc.
NORTHBROOK, Ill, Sept. 25, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today reported top-line results from the Company's ongoing Phase 3 study of CLR-610, the Company's proprietary oral...
clarus_final_indentity.jpg
Clarus Therapeutics Strengthens Patent Estate with Issuance of a U.S. Patent Directed to Formulations and Method of Use of Clarus' Oral Testosterone Product
September 19, 2012 08:00 ET | Clarus Therapeutics, Inc.
NORTHBROOK, Ill, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,241,664 entitled, "Pharmaceutical...